Who are Avatrombopag Oral Tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Promacta, Nplate, Revolade®, CsA+Herombopag, Herombopag + CsA, Doptelet Pill.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/avatrombopag-oral-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Avatrombopag Oral Tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Avatrombopag Oral Tablet (Avatrombopag Oral Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thrombopoietin receptor agonist. Area: Hematology.

marketed Thrombopoietin receptor agonist TPO receptor (c-Mpl) Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Avatrombopag Oral Tablet (Avatrombopag Oral Tablet) — Sobi, Inc.. Avatrombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow megakaryocytes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Avatrombopag Oral Tablet TARGET	Avatrombopag Oral Tablet	Sobi, Inc.	marketed	Thrombopoietin receptor agonist	TPO receptor (c-Mpl)
Promacta	ELTROMBOPAG	Novartis	marketed	Thrombopoietin Receptor Agonist	Thrombopoietin receptor	2008-01-01
Nplate	ROMIPLOSTIM	Amgen	marketed	Thrombopoietin Receptor Agonist [EPC]	Thrombopoietin receptor	2008-01-01
Revolade®	Revolade®	Centro de Atencion e Investigacion Medica	marketed	Thrombopoietin receptor agonist	TPO receptor (TPOR/MPL)
CsA+Herombopag	CsA+Herombopag	Peking Union Medical College Hospital	marketed	Combination therapy: calcineurin inhibitor + thrombopoietin receptor agonist	Calcineurin (CsA); thrombopoietin receptor / MPL (herombopag)
Herombopag + CsA	Herombopag + CsA	Peking Union Medical College Hospital	marketed	Thrombopoietin receptor agonist + Calcineurin inhibitor	TPO receptor (c-Mpl) + Calcineurin
Doptelet Pill	Doptelet Pill	Hvidovre University Hospital	marketed	Thrombopoietin receptor agonist	TPO receptor (TPOR/MPL)

Recent regulatory actions (last 90 days)

2026-03-16 — Promacta · FDA · approved · US · Novartis

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thrombopoietin receptor agonist class)

Centro de Atencion e Investigacion Medica · 2 drugs in this class
Institute of Hematology & Blood Diseases Hospital, China · 2 drugs in this class
Jiangsu HengRui Medicine Co., Ltd. · 2 drugs in this class
Hvidovre University Hospital · 1 drug in this class
Kyowa Kirin Korea Co., Ltd. · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
PharmaEssentia Japan K.K. · 1 drug in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class
Shenyang Sunshine Pharmaceutical Co., LTD. · 1 drug in this class
Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Avatrombopag Oral Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/avatrombopag-oral-tablet. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab